News | March 10, 2008

Bayer HealthCare Opens New Door to Tracking Contrast Media

March 11, 2008 – Bayer HealthCare Pharmaceuticals Inc. unveiled plans to launch VistaTrak, a contrast media management system that provides a new management tool designed to help enhance patient care and safety, optimize inventory management and improve billing accuracy.

VistaTrak is a collaboration between Bayer HealthCare Pharmaceuticals and Mobile Aspects, a provider of Radio Frequency Identification (RFID)-enabled solutions for healthcare and hospital environments. The companies worked together to optimize Mobile Aspects’ proprietary iRIS platform for clinical environments that use contrast media. Bayer is the first company to offer a contrast media management system based on an RFID platform to automate manual processes and capture valuable operational data that currently cannot be found in any one system.

The system combines RFID technology of “tagged” bottles of contrast agent with a “smart” cabinet and a specially designed interface to capture, store and manage product utilization data easily and reliably while helping to reduce the risk of human error. It provides solutions for the use of contrast media, such as:
• Facilitating patient safety by automatically screening data from a patient’s electronic medical record (EMR) for, among other things, contraindications and prior adverse events
• Capturing information stored on the tag, such as NDC number, expiration date and lot number, automatically and in an efficient manner that supports compliance with accrediting organization requirements
• Providing contrast dosing information to improve billing accuracy and help address any existing issues with reimbursement or audits
• Tracking inventory to enable departments to order and manage inventory more efficiently and reduce waste

VistaTrak features a touch-screen interface and is available in two different sizes to address varying usage needs.

For more information: www.pharma.bayer.com

Related Content

Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...
Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...
Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...
Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018
Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to create magnetic...